2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3885 Chronic lymphocytic leukemia in young patients: Characteristics and outcomes in the modern era of treatment

Amneet Kaur Bajwa, MD, Joshua Wiesner, MD2, Aarij Gora, BS3, Shefeera Raji-Khalid, BS4, Ying Huang, MA, MS5, Aseel Alsouqi, MD6, Seema Ali Bhat, MD7, Michael Grever, MD8, Kerry A. Rogers, MD9, Adam Kittai, MD10, Jennifer A. Woyach, MD11
1 James Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 James Comprehensive Cancer Center, Columbus, Ohio, United States
6 James Comprehensive Cancer Center, Columbus, Ohio, United States
7 James Comprehensive Cancer Center, Columbus, Ohio, United States
8 James Comprehensive Cancer Center, Columbus, Ohio, United States
9 James Comprehensive Cancer Center, Columbus, Ohio, United States
10 NYU Langone Comprehensive Cancer Center, New York City, New York, United States
11 James Comprehensive Cancer Center, Columbus, Ohio, United States

Introduction: While most commonly a disease of older adults, approximately 10% of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) cases are diagnosed in patients (pts) younger than 55 years (yrs) (Siegel et al, SEER Cancer Stats). Previous studies have reported higher CLL-related mortality in younger pts, especially patients with high-risk disease features who have reduced overall survival (OS) as compared to the general population (Becerra et al., Cherng et al., Mauro et al., Parikh et al.). Most research investigating CLL in younger pts was completed in the era of chemoimmunotherapy with limited data available for pts treated with novel agents. Here, we aim to study the characteristics and outcomes of young CLL pts in the era of targeted therapies.

Methods: This is an IRB approved, retrospective study of pts with CLL diagnosed at age ≤55 yrs and seen at The Ohio State University from 01/2010 to 01/2026. Pts who received chemotherapy were excluded. Medical records were reviewed for patient/disease characteristics and outcomes. Descriptive statistics were used to present these data. OS was calculated from date of diagnosis and estimated using the method of Kaplan-Meier and associated with patient characteristics through the Cox Proportional Hazards model.

Results: A total of 219 pts were included, 59.% of whom were male. Eighty-nine percent of pts were White, 7.4% were Black and 4.2% were categorized as Other race. Median age at diagnosis was 43 yrs (range 17-55) with 3.7% ≤30 yrs, 31.5% 30 to ≤40 yrs, and 64.8% 40 to ≤55 yrs old. Out of 192 pts (87.6%) who had IGHV mutational testing, 106 pts (55.2%) had IGHV unmutated (uIGHV) disease. FISH testing was completed in 212 pts (96.8%) and the most common abnormality was del13q (44.8%), followed by normal FISH (31.1%), trisomy 12 (19.3%), del11q (12.7%) and del17p (3.3%). Complex karyotype was present in 14.2% of the 190 patients who were tested. Rai/Binet Stage was 0 or A in 93 pts (42.9%), I-II or B in 112 pts (51.6%), and III-IV or C in 12 pts (5.5%). Thirty-nine pts (18.2%) were symptomatic at diagnosis, and 175 pts (81.8%) were asymptomatic. Richter transformation occurred in 9 pts (4.1%) with 4  of these pts undergoing .

With a median follow up of 5.7 yrs (range 0-20.8), 113 pts (51.6%) received therapy for CLL. Of the 27 pts with complex karyotype, 20 pts (74%) received treatment and 76 pts (71.6%) out of those with uIGHV received treatment. Median lines of CLL therapy were 1 (range 0-5). Eighty-four pts (38.4%) received 1 treatment and 29 (25.6%) received 2 or more treatments. Fifty-four (47%) of the total pts who underwent treatment received frontline continuous BTK inhibitor while 47 (40.9%) received a fixed-duration regimen. Ninety-eight percent of patients received fixed-duration treatment were treated with a venetoclax combination. One-year cumulative incidence rate (CIR) for starting CLL treatment was 16.9%, 3-year CIR was 32.9%, and 5-year CIR was 49.5%. In pts who lived with CLL for at least 10 yrs (n=49), (range 0-12.9) and median total duration off treatment was 9.8 yrs (range 0.7-17.4).

OS from CLL diagnosis was 95.1% at 5-yrs (95% CI 90.5-97.6) and 89.8% at 10 yrs (95% CI 81.5-94.5). Five-year and 10-year OS from first CLL treatment was 92.9% (95% CI 84.7-96.8%) and 87.4% (95 % CI 69.6-95.1) respectively. Overall, 15 pts (6.8%) died, with 5 deaths secondary to CLL or RT.

Multivariable analysis for starting CLL treatment demonstrated increased risk with Rai stage III-IV/Binet C (HR 5.17, 95% CI 1.62-16.50, p=0.01(HR 1.28, 95% CI 1.11-1.48, p=0.0007), and symptoms at diagnosis (HR 2.21, 95% CI 1.19-4.13, p=0.01). Univariable analysis for OS from CLL diagnosis demonstrated that symptomatic disease at diagnosis was a significant risk factor with HR 3.97 (95% CI 1.38-11.47, p=0.01).

Conclusion: In this cohort of pts diagnosed with CLL at age ≤ 55 yrs, most had intermediate-stage and uIGHV disease. Our data demonstrates that of those pts who required treatment, approximately 50% started treatment within 5 yrs of diagnosis. High risk disease characteristics were associated with an increased risk of starting treatment; and symptomatic disease at presentation was associated with a reduced OS. Overalldemonstrated excellent 10-year OS rates of 89.8% from diagnosis and 87.4% from treatment start in the era of targeted therapy.

Amneet Kaur Bajwa, MD: No relevant conflicts of interest to declare.